1Y Close · As of Aug 26, 2026
Genome&Company operates in the Pharmaceuticals sector.
Legal name: Genome&Company
In fiscal year 2025, Genome&Company (314130) reported revenue of 24.6 billion KRW, down 11.4% from 27.7 billion KRW a year earlier.
Operating profit was -29.2 billion KRW and net income was -7.7 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 211.6 billion KRW, with a P/B of 1.85.
These figures can be verified in the DART filing (receipt no. 20260320001084).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 24.6B | -29.2B | -7.7B |
| 2024 | 27.7B | -24.2B | -26.8B |
| 2023 | 14.3B | -55.1B | -50.7B |
Recent Filings
Extraordinary Meeting Result
Large Shareholding Report (General)
Stock Option Grant Report
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-21 | Extraordinary Meeting Result |
| 2026-08-21 | Large Shareholding Report (General) |
| 2026-08-21 | Stock Option Grant Report |
| 2026-08-18 | Derivative Trading Loss |
| 2026-08-14 | Semi-Annual Report (2026.06) |